Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome

Aims Influenza infection has been shown to accentuate the progression of atherosclerosis and precipitate the occurrence of acute coronary syndrome (ACS). However, the protective effects of the influenza vaccine on cardiovascular events are still inconclusive. Methods and results The study was a pros...

Full description

Saved in:
Bibliographic Details
Main Authors: Arintaya Phrommintikul, Srun Kuanprasert, Wanwarang Wongcharoen, Rungsrit Kanjanavanit, Romanee Chaiwarith, Apichard Sukonthasarn
Format: Journal
Published: 2018
Subjects:
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79953222097&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/50203
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-50203
record_format dspace
spelling th-cmuir.6653943832-502032018-09-04T04:26:24Z Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome Arintaya Phrommintikul Srun Kuanprasert Wanwarang Wongcharoen Rungsrit Kanjanavanit Romanee Chaiwarith Apichard Sukonthasarn Medicine Aims Influenza infection has been shown to accentuate the progression of atherosclerosis and precipitate the occurrence of acute coronary syndrome (ACS). However, the protective effects of the influenza vaccine on cardiovascular events are still inconclusive. Methods and results The study was a prospective randomized open with blinded endpoint (PROBE) study. The 439 patients who had been admitted due to ACS within 8 weeks were enrolled and randomly allocated to receive inactivated influenza vaccine in the vaccine group and no treatment in the control group. All patients were treated with the standard therapy including revascularization according to primary cardiologists. The primary endpoint, which was the combined major cardiovascular events, including death, hospitalization from ACS, hospitalization from heart failure, and hospitalization from stroke, occurred less frequently in the vaccine group than the control group [9.5 vs. 19.3%, unadjusted HR 0.70 (0.57-0.86), P = 0.004]. There was no significant difference in the incidence of cardiovascular death between the vaccine and control groups [2.3 vs. 5.5, unadjusted HR 0.39 (0.14-1.12), P = 0.088]. Conclusion The influenza vaccine reduced major cardiovascular events in patients with ACS. Therefore, it should be encouraged as a secondary prevention in this group of patients. © 2011 The Author. 2018-09-04T04:26:24Z 2018-09-04T04:26:24Z 2011-07-01 Journal 15229645 0195668X 2-s2.0-79953222097 10.1093/eurheartj/ehr004 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79953222097&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/50203
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
topic Medicine
spellingShingle Medicine
Arintaya Phrommintikul
Srun Kuanprasert
Wanwarang Wongcharoen
Rungsrit Kanjanavanit
Romanee Chaiwarith
Apichard Sukonthasarn
Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome
description Aims Influenza infection has been shown to accentuate the progression of atherosclerosis and precipitate the occurrence of acute coronary syndrome (ACS). However, the protective effects of the influenza vaccine on cardiovascular events are still inconclusive. Methods and results The study was a prospective randomized open with blinded endpoint (PROBE) study. The 439 patients who had been admitted due to ACS within 8 weeks were enrolled and randomly allocated to receive inactivated influenza vaccine in the vaccine group and no treatment in the control group. All patients were treated with the standard therapy including revascularization according to primary cardiologists. The primary endpoint, which was the combined major cardiovascular events, including death, hospitalization from ACS, hospitalization from heart failure, and hospitalization from stroke, occurred less frequently in the vaccine group than the control group [9.5 vs. 19.3%, unadjusted HR 0.70 (0.57-0.86), P = 0.004]. There was no significant difference in the incidence of cardiovascular death between the vaccine and control groups [2.3 vs. 5.5, unadjusted HR 0.39 (0.14-1.12), P = 0.088]. Conclusion The influenza vaccine reduced major cardiovascular events in patients with ACS. Therefore, it should be encouraged as a secondary prevention in this group of patients. © 2011 The Author.
format Journal
author Arintaya Phrommintikul
Srun Kuanprasert
Wanwarang Wongcharoen
Rungsrit Kanjanavanit
Romanee Chaiwarith
Apichard Sukonthasarn
author_facet Arintaya Phrommintikul
Srun Kuanprasert
Wanwarang Wongcharoen
Rungsrit Kanjanavanit
Romanee Chaiwarith
Apichard Sukonthasarn
author_sort Arintaya Phrommintikul
title Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome
title_short Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome
title_full Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome
title_fullStr Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome
title_full_unstemmed Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome
title_sort influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome
publishDate 2018
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79953222097&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/50203
_version_ 1681423547537293312